

The Breast Cancer Intergroup



The Breast Cancer Intergroup of North America (TBCI)

Chair: William Wood, M.D.
Emory University

NCI liaison: JoAnne Zujewski, M.D.
NCI/CTEP

ACOSOG

Breast committee chair:
Kelly Hunt, M.D.

CALGB

Breast committee co-chairs:
Clifford Hudis, M.D.
Eric Winer, M.D.

ECOG

Breast committee chair:
George Sledge, M.D.

NCCTG

Breast committee chair:
Edith Perez, M.D.

NCIC CTG

Breast committee chair:
Kathleen Pritchard, M.D.

SWOG

Breast committee chair:
Gabriel Hortobagyi, M.D.,
F.A.C.P.

Correlative science:
Daniel Hayes, M.D.

NSABP

RTOG

BIG

EORTC

IBCSG

TBCI Chair and NCI-CTEP Liason

<http://ctep.cancer.gov/resources/tbci>

- **TBCI Chair:**

William Wood, M.D.

**Chairman, Department of Surgery, Emory University
School of Medicine**

Phone: 404-727-5800

Email: William_Wood@emoryhealthcare.org

- **NCI liaison to TBCI:**

JoAnne Zujewski, M.D.

Senior Investigator, NCI-CTEP

Phone: 301-496-2522

Email: ZujewskJ@mail.nih.gov

TBCI Mission

TBCI is dedicated to the study and advancement of breast cancer therapies through Intergroup collaboration on NCI-sponsored clinical trials.

This mission includes promoting investigation into biologic correlates in breast cancer through performance of correlative and companion studies associated with these trials.

TBCI Correlative Sciences Committee

http://ctep.cancer.gov/resources/tbci/correlative_studies.html

- **TBCI-CSC Chair:**

Daniel F. Hayes, M.D.
Clinical Director, Breast Oncology Program
University of Michigan Comprehensive Cancer Center
Phone: 734-615-6725
Email: hayesdf@umich.edu

- **NCI liaison to TBCI:**

JoAnne Zujewski, M.D.
Senior Investigator, NCI-CTEP
Phone: 301-496-2522
Email: ZujewskJ@mail.nih.gov

<http://ctep.cancer.gov/resources/tbci>

TBCI Breast Cancer Specimens Available for Research Correlative Sciences Committee

Below please find instructions to investigators seeking to request Breast Cancer Intergroup specimens for use in correlative scientific studies.

[Announcement: IBCSG call for Proposals by February 1, 2008](#) (Proposals for requests of banked FFPE samples from BIG 1-98 or other studies to be received at the IBCSG Pathology Office by February 1, 2008.) For application, agreements, available material and other information, please see the **[IBSCG Pathology Corner webpage](#)**

[TBCI Correlative Science Proposal Submission Form](#) (Please use this form to submit your request for specimens. Proposals will be rigorously reviewed by the Correlative Sciences Committee for scientific merit.)

[Funding](#)

[Introduction](#)

[Specimens available from TBCI closed trials](#)

[Active TBCI trials](#) (specimen collection still underway)

[Instructions to Investigators/FAQs](#)

[Contacts for the Committee](#)

[Contacts for TBCI specimen banks](#)

[Proposals approved by the Committee](#)

[TBCI Home](#) (Home page of TBCI, a network of six NCI-supported Cooperative Groups: ACOSOG, CALGB, ECOG, NCIC CTG, NCCTG, and SWOG)

[Translational Research Working Group \(TRWG\)](#)

[Office of Biorepositories and Biospecimen Research \(OBBR\)](#)

[REMARK guidelines for publications of tumor marker studies](#)

[Specimen collection guidelines for breast cancer Group trials](#)

[NSABP tissue bank](#)

[Other NCI-Supported Specimen Resources](#)

TBCI CSC Available Specimens

http://ctep.cancer.gov/resources/tbci/correlative_studies.html#summary

| Clinical trial protocol number | Title | Study arms | Protocol description (PDQ) | Approx # cases with usable blocks in TBCI banks | Approx # cases with usable unstained slides | TMA? | Specimen submission specified by protocol | Patients accrued | Groups storing specimens |
|--------------------------------|---|---|--|---|---|--------------------------------|---|------------------|--------------------------|
| C9741 | Phase III Randomized Study of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed By Paclitaxel at 14 and 21 Day Intervals in Women With Node Positive Stage II or IIIA Breast Cancer | Arm I: Sequential A, paclitaxel, C, Q3W Arm II: Sequential A+ G-CSF, paclitaxel + G-CSF, C + G-CSF Q2W Arm III: Concurrent AC followed by paclitaxel Q3W Arm IV: Concurrent AC + G-CSF followed by paclitaxel + G-CSF Q2W Patients receive tamoxifen and RT post-chemo. | Protocol Description (PDQ) | 1,407 cases with usable blocks | 326 cases with usable slides | TMA in progress ; ~1,429 cases | Paraffin block of primary tumor | 2,005 patients | CALGB, ECOG, NCCTG, SWOG |

etc. (See website for complete specimen inventory)

Productivity

- **14 Approved Concepts/33 markers from 9 clinical trials**
 - C9344 multiple assays for HER2, p53
 - C9741 multiple assays for HER2, ki67
 - E2100 snps in VEGF, KDR
 - E2197 21 gene RS, multiple other genes by rtPCR
 - MA17 “2 gene”, 21 gene RS, COX2, CYP19, GATA3, NAT1, mult genes rtPCR
 - N9831 myc, TOP2A, IGFR1, PTEN
 - S8814 21 gene RS; multiple other genes by rtPCR
 - S8897 snps in multiple genes related to chemoRx activity and metabolism
 - S9313 p27, cycl E, HER2, TOP2A, ER, PgR, p53, HER2 by IHC and AQUA
 - S0221 snps in multiple genes related to chemoRx activity and metabolism
- **2 manuscripts (JNCI, NEJM)**
- **5 abstracts (ASCO, AACR, SABCS)**
- **3 RO1s**
- **Consolidated tissues in lead Group PCOs for each trial**
- **“Blanket” permission**
 - TMA construction
 - ER, PgR, HER2 analysis using standard assays
- **Outside funding (BCRF)**
 - \$50K/approved concept
 - PCO infrastructure (TMA, routine staining)
 - Summits
 - PGRN/TBCI March 30/31 2008: Pharmacogenomics in TBCI